Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus bv-77
- Development stage
- Preclinical
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus bv-77 is a specific strain of probiotic bacteria isolated from healthy human breast milk. [2] It is being investigated for its potential health benefits, including the regulation of fat metabolism, gut health, and antioxidant properties. [2] As a live biotherapeutic product, it functions by modulating the gut microbiota. A clinical trial (NCT07400367) is evaluating L. rhamnosus bv-77 as part of a four-strain probiotic combination product for the treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). [3] The proposed mechanism involves improving the gut-liver axis to reduce hepatic inflammation and abnormal lipid metabolism. [3] Preclinical studies in rats have shown that L. rhamnosus bv-77, alone and in combination with other probiotics, can alleviate body fat formation and reduce plasma cholesterol levels. [4] The strain is provided by Glac Biotech Co., Ltd. [4]
- Other names
- Lactobacillus rhamnosus bv-77
Beyond the preview
Go deeper on Lactobacillus rhamnosus bv-77.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus rhamnosus bv-77.